|Chemical and physical data|
|Molar mass||491.58 g·mol−1|
|3D model (JSmol)|
PipISB is a drug used in scientific research which acts as a potent and selective inverse agonist of the cannabinoid receptor CB1. It is highly selective for the CB1 receptor over CB2, with a Kd at CB1 of 1.5nM vs over 7000nM at CB2, has good blood-brain barrier penetration, and can be conveniently radiolabelled with either 11C or 18F, making it useful for mapping the distribution of CB1 receptors in the brain.
- Donohue SR, Halldin C, Schou M, Hong J, Phebus L, Chernet E, et al. (2008). "Radiolabeling of a high potency cannabinoid subtype-1 receptor inverse agonist, N-(4-fluoro-benzyl)-4-(3-(piperidin-1-yl-indole-1-sulfonyl)benzamide (PipISB), with carbon-11 or fluorine-18". Journal of Labelled Compounds and Radiopharmaceuticals. 51 (3): 146. doi:10.1002/jlcr.1491.
- Finnema SJ, Donohue SR, Zoghbi SS, Brown AK, Gulyás B, Innis RB, et al. (January 2009). "Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo". Synapse. 63 (1): 22–30. doi:10.1002/syn.20578. PMC 2587077. PMID 18925657.